BACKGROUND: Partial pituitary desensitization using gonadotrophin-releasing hormone (GnRH) agonists may be sufficient in women undergoing controlled ovarian hyperstimulation for assisted reproduction. However, the minimal effective agonist dose remains to be determined. The aim of the study was to investigate the effect of a reduced daily dose of triptorelin, administered at the start of ovarian stimulation, on the results of IVF and intracytoplasmic sperm injection. METHODS: A total of 132 patients was randomized in two groups. Pituitary desensitization was obtained in group 1 (66 patients) with a single 3.75 mg injection (i.m.) of triptorelin. In group 2, 66 patients received 100 µg triptorelin daily, which was then reduced to 50 µg at the start of follicle-stimulating hormone (FSH) stimulation. RESULTS: No significant differences were found in terms of pregnancy rate per transfer (38% in group 1 versus 34.9% in group 2), implantation rate (20.2 versus 18%) and abortion rate (8.3 versus 9.1%). The number of FSH ampoules used, as well as the number of days stimulation required, was significantly reduced in group 2 (41 ⍨ 26 versus 46.6 ⍨ 25.3, P < 0.03 and 11 ⍨ 1.3 versus 11.8 ⍨ 1.5, P < 0.002 respectively). No significant differences were seen in oestradiol concentrations and in follicle number, in the quantity of oocytes collected and fertilized, or in the number of embryos obtained or transferred. CONCLUSION: A reduced dose of triptorelin is enough for pituitary suppression during ovarian stimulation but provides no significant improvement in IVF cycle outcome when compared with depot formulation. The possibility of a shorter treatment protocol requiring lower amounts of gonadotrophins should be considered in view of its economic advantage.
Introduction
, and has a long lasting, potentially detrimental, effect in the luteal phase. What is more, GnRH agonist has been Over the last ten years, pre-treatment with gonadotrophinshown to have a direct effect on ovarian steroidogenesis releasing hormone (GnRH) agonists in women undergoing (Casper and Yen, 1979; Tureck et al., 1982; Parinaud et al. , controlled ovarian hyperstimulation (COH) for assisted repro-1988) and specific GnRH receptors have been found in murine duction has became very common in almost all IVF centres.
and human granulosa cells (Bramley et al., 1985 ; Latouche The suppression of pituitary gonadotrophin secretion before et al., 1989) . and during induction of multiple follicular growth has some Several authors have suggested that partial pituitary desensitbenefits, including: (i) prevention of premature luteinizing ization in an assisted reproduction procedure might be sufficient hormone (LH) surge and luteinization, resulting in a lower (Balasch et al., 1992a; Simon et al., 1994) , but the minimal cancellation rate; (ii) improvement in follicular recruitment effective dose of GnRH agonists needed to avoid premature with a larger number of oocytes recovered both in normal and LH surge during ovarian stimulation has not yet been clearly poor responders; (iii) improvement in routine organization of determined. Some authors (Broekmans et al., 1996 ; Janssens assisted reproduction (Zorn et al., 1987) . The widespread et al., 1998) showed, with the use of GnRH challenge tests, use of long-acting GnRH agonist formulations has increased that comparable degrees of suppression of the pituitary can be patients' and clinicians' convenience. However, it has been achieved with either 100 or 50 µg/day triptorelin. Lower doses suggested that complete pituitary desensitization achieved by such as 25 µg/day (Broekmans et al., 1996) or 15 µg/ long-term use of GnRH agonist has the disadvantages of day (Janssens et al., 1998) 
Materials and methods
Pregnancy was defined as the presence of one or more gestational sacs detected on ultrasound scan performed at least 4 weeks after Protocol embryo transfer. Biochemical pregnancies (a rise of β-HCG with no From September 1998 to September 1999, 132 women undergoing further evidence of gestational sac on ultrasound scan) were not COH for IVF or ICSI were enrolled in the study. All subjects were considered. aged between 25 and 38 years with infertility caused by tubal, idiopathic or male factors. Cases with active endometriosis or only Parameters evaluated one ovary, or with follicle-stimulating hormone (FSH) concentrations
The primary endpoint was the total number of oocytes retrieved from Ͼ15 IU/l on day 3 of the menstrual cycle, were excluded from patients who received HCG. The following secondary endpoints were the study. Patients with a previous COH requiring high doses of also recorded: number of FSH ampoules used, number of days gonadotrophins in a long GnRH agonist protocol or, conversely, a of stimulation, 17β-oestradiol concentration on the day of HCG known history of risk of severe hyperstimulation were also excluded.
administration, LH on day 7 of stimulation and on the day of HCG Eligible patients who agreed to participate were randomized in two administration, progesterone on the day of HCG administration, treatment groups. In group 1 (standard protocol, 66 patients), pituitary number of follicles (total and Ͼ17 mm in diameter) on the day of desensitization was performed with a single i.m. injection of tripto-HCG administration, number of oocytes collected, number of mature relin, 3.75 mg (Decapeptyl ® 3.75; Ipsen Spa, Milan, Italy), on day oocytes, fertilization rate, number of cleaved embryos, number 21 of the cycle preceding treatment.
of embryos transferred or frozen, number of clinical pregnancies, Group 2 patients (66 patients) received a daily s.c. injection of miscarriages and multiple pregnancies. 100 µg triptorelin (Decapeptyl ® 0.1, Ipsen Spa), starting from day 21 of the cycle preceding treatment. At the onset of menses (start Sample size time of FSH stimulation) the dose was reduced to 50 µg s.c. daily A sample size of 66 patients in each group would have 90% power until the day of human chorionic gonadotrophin (HCG) administration.
and a significance level of 0.05 to detect a difference in the mean At the onset of menses, patients in both groups began ovarian number of oocytes of 2.3 (SD 6.5). stimulation with highly purified urofollitropin (Metrodin ® HP 75, Assignment Serono, Milan, Italy). The stimulation protocol comprised 4 ampoules (300 IU) daily for 2 days and 2 ampoules (150 IU) daily for 4 days; Randomization was performed on an individual basis using sealed the dose was then adjusted according to individual response as envelopes containing the name of one of the two treatments. The assessed by 17β-oestradiol assays and ultrasound scanning performed assignment took place when eligible patients agreed to participate, every other day. about 2 weeks before the day of triptorelin administration. Each HCG (Profasi ® HP; Serono), 10 000 IU, was administered when envelope and allocation was sequentially numbered. The contents of one or more follicles reached a maximal diameter Ͼ23 mm, with the envelopes were only known to medical staff who had no involvement with the trial. oestradiol concentrations corresponding to the number of follicles. of this study, which is still ongoing. The 95% confidence interval (CI) around the point estimates of the effect of treatment were calculated for all the primary and Table I shows the characteristics of the ovarian stimulation secondary endpoints. in the two groups of patients. The number of FSH ampoules used was lower in group 2 (41 Ϯ 26 versus 46.6 Ϯ 25.3 in group 1, P Ͻ 0.03). Days of stimulation were significantly Results lower in group 2 (11 Ϯ 1.3 versus 11.8 Ϯ 1.5, P Ͻ 0.002).
Statistical analysis

Participant flow and follow up
No significant difference was seen in oestradiol concentrations and in the number of follicles (total and Ͼ17 mm) seen on A total of 132 patients was randomized into the study; 66 into depot triptorelin group (group 1) and 66 into daily triptorelin the day of HCG administration or of total oocytes collected. The number of mature oocytes was significantly higher in the group (group 2). Patients' mean age was comparable in the two groups: 33 Ϯ 3.6 years in group 1 and 33.8 Ϯ 3.1 years 3.75 triptorelin group (Table I) , but no differences were detected in the number of fertilized oocytes or embryos in group 2 (Table I ). Of the 132 randomized patients, 128 had oocyte retrieval and 126 completed the study up to embryo obtained/transferred. If ICSI patients only (in which an evaluation of oocyte transfer. In total four cycles were cancelled before oocyte retrieval for poor response to stimulation and were not included nuclear maturity is feasible) are considered, no significant differences were found between the two groups in the number in efficacy analyses (two in both groups). Figure 1 shows the participant flow and follow-up.
of metaphase II oocytes (12 Ϯ 4.6 in group 1 versus 11 Ϯ 3.5 in group 2). IVF was performed in 33 patients in group 1 and in 35 patients in group 2. ICSI was performed in 31 patients in LH concentrations were lower in the depot triptorelin group: on day 7 of stimulation the difference was not significant (0.91 group 1 and in 29 patients in group 2. One patient in group 1 and one in group 2 did not undergo embryo transfer because Ϯ 0.48 IU/l in group 1 versus 1.06 Ϯ 0.41 IU/l in group 2: P ϭ 0.06), but it became highly significant on the day of HCG of failed fertilization. (Table II) . Progesterone on arly defined. the day of HCG administration was low in both groups (0.52 Some authors have suggested that only partial pituitary Ϯ 0.24 ng/ml in group 1 versus 0.43 Ϯ 0.07 ng/ml in group 2). desensitization in an assisted reproduction procedure might be Clinical results are summarized in Table III . No significant sufficient and have put forward protocols using reduced GnRH differences were found in terms of pregnancy rate per transfer agonist doses. As regards depot formulation, both the full (24/63 ϭ 38% in group 1 versus 22/63 ϭ 34.9% in group 2), (3.75 mg) and half (1.87 mg) dose of GnRH agonist triptorelin implantation rate (29/143 ϭ 20.2% in group 1 versus 25/ seem to be equally effective in pituitary desensitization, with 139 ϭ 18% in group 2) and abortion rate (2/24 ϭ 8.3% in similar duration for both desensitization and recovery time group 1 versus 2/22 ϭ 9.1% in group 2). One pregnancy in (Balasch et al., 1992a) . group 1 was ectopic.
No difference in terms of stimulation quality and IVF To date, almost all patients who agreed to have embryos outcome was reported (Porcu et al., 1994 (Porcu et al., , 1995 in two frozen and did not conceive in their first transfer cycle have different studies comparing a depot and a daily administered undergone embryo thawing. Seven patients conceived in the form of GnRH agonist (triptorelin 3.75 mg, 1 ampoule i.m. long acting triptorelin group and eight in the low dose daily versus triptorelin 100 µg s.c. daily and leuprorelin 3.75 mg, triptorelin group. No significant difference was seen in the 1 ampoule i.m. versus buserelin 0.3 mg s.c. daily respectively). cumulative pregnancy rates between the two groups (31/63 ϭ
The clinical results of our research confirm such studies, 49% in group 1 versus 30/63 ϭ 47.6% in group 2). however, the daily dose administered during stimulation in those studies remained unchanged throughout treatment and Discussion was not reduced as in ours. The most widely used protocol for administration of GnRH Indeed, there is some evidence that once the pituitary is analogues in assisted reproduction centres today involves the suppressed, the dose of GnRH agonist needed to prevent the use of depot formulation, which usually induces pituitary LH surge decreases with the length of treatment (Sandow and suppression for a long time after oocyte retrieval. Two studies Donnez, 1990) . Halving the dose of a daily administered showed that recovery of pituitary function begins only 8 weeks GnRH agonist at the beginning of stimulation has been after a single dose injection of depot triptorelin (Porcu et al., successfully performed both in normal (Elgendy et al., 1998 (Elgendy et al., ) 1994 or depot leuprorelin (Porcu et al., 1995) . In contrast, an and poor (Feldberg et al., 1994; Olivennes et al., 1996) almost normal response to GnRH challenge test was seen responders, with no adverse effect on the quality of ovarian 1 week after discontinuation of a daily administered form of response to stimulation. GnRH agonist (Porcu et al., 1994 (Porcu et al., , 1995 .
Our results, in agreement with Feldberg (Feldberg et al., A key benefit of GnRH agonist lies in its inhibiting effect 1994) and Olivennes (Olivennes et al., 1996) , show a shorter on the endogenous secretion of LH. However, concern has stimulation phase and a lower number of FSH ampoules been raised about excessive pituitary suppression, especially administered in the low dose s.c. GnRH agonist group. Howin poor responder patients, resulting in reduced ovarian ever, unlike the above reports, we did not find better ovarian response and a need for higher gonadotrophin dosage for response with low dose GnRH agonist. In our study ovarian stimulation. Furthermore, it is now well known that GnRH stimulation did not change with the two different GnRH analogues have extra-pituitary collateral effects, including a agonist regimens, showing similar oestradiol concentrations direct effect on ovarian steroidogenesis. An inhibitory action and number of follicles recruited on the day of HCG administrahas been suggested by various authors with in-vitro studies tion and oocytes collected. The number of oocytes classified (Tureck et al., 1982; Parinaud et al., 1988; Smitz et al., 1992) .
as 'mature' via cumulus-oocyte complex examination was In light of the above, using low doses of this kind of drug significantly higher in the depot triptorelin group. However oocyte quality, as measured by the number of metaphase II would seem appropriate (Loumaye et al., 1989) , though the oocytes (ICSI patients only), as well as fertilization and studies which showed no differences in hormonal profile in the luteal phase with both GnRH analogues (Porcu et al., implantation rates were similar, with no apparent adverse effects of low dose triptorelin on embryo quality. 1994). Despite the different duration of pituitary suppression, depot formulations do not seem to impair luteal function Elgendy et al. studied the effect of a reduced dose of a different GnRH agonist, nafarelin acetate, administered as and fetal development, more than daily-administered forms. Luteal support is necessary with both formulations, as has an intranasal spray in young, normally-responding women (Elgendy et al., 1998) . Unlike our study, they found no recently been confirmed (Beckers et al., 2000) . Our study confirms that a low dose of triptorelin is difference in the number of ampoules of gonadotrophins used nor in the length of stimulation required, though the number capable of inducing adequate pituitary suppression during ovarian stimulation. Although this dose does not significantly of oocytes and of embryos available for transfer or freezing were higher in the low dose GnRH agonist group. However, improve IVF outcome, the possibility of a shorter treatment, requiring a lower amount of gonadotrophins, should be as in our study, the pregnancy rate was similar in both GnRH agonist regimens.
taken into consideration on account of its economic advantage. If we also consider the result of embryo freezing no difference was found in our study in the cumulative pregnancy It may be sensible to adopt a case-by-case approach, weighing up the convenience of a single i.m. administration rate between the two groups. This is not so surprising if we consider that the number and quality of embryos frozen were with the risk of higher treatment costs against the discomfort of multiple injections, albeit with lower costs. similar in both groups.
A daily dose of 50 µg triptorelin has proven sufficient Additional studies are needed to evaluate the benefit of further reducing the dose of GnRH agonist on the outcome to prevent the spontaneous LH surge (Broekmans et al., 1996; Janssens et al., 1998) . None of our patients seemed of assisted reproduction. to have ovulated before oocyte retrieval: LH or progesterone assay performed on the day of HCG administration showed no evidence of an LH surge or premature luteinization.
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